PACB Pacific Biosciences of California Inc.

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time.

The call will be webcast and may be accessed at PacBio’s website at .

Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT)

Listen live via internet or replay:

Toll-free: 1-888-349-0136

International: 1-412-317-0459

If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q3 Earnings Call.”

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Todd Friedman

Media:



EN
10/10/2024

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major ...

PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 New long-read sequencing chemistry reduces DNA input requirements four-fold, enables a 33% increase in data output per SMRT Cell, improves methylation calling, and expands support for multiomics MENLO PARK, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced SPRQ, an improved sequencing chemistry for its . The new chemistry will reduce Revio DNA input requ...

October 29, 2024 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compa...

PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby broadening the range of sequencing solutions available to researchers worldw...

October 22, 2024 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Enters Cancer Genomics Research Collaboration in Singapore with...

PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's adv...

October 11, 2024 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2...

PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024 MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio’s website at . Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call...

October 10, 2024 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate...

PacBio, A*STAR, and Macrogen Unveil State-of-the-Art Lab to Accelerate Genomics Innovation in Singapore The new lab will leverage PacBio’s HiFi sequencing technology to broaden access to highly accurate long-read sequencing and multi-omics solutions in Southeast Asia SINGAPORE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the Agency for Science, Technology, and Research (A*STAR), and Macrogen, today announced the opening of a state-of-the-art joint laboratory at A*STAR Genome Ins...

October 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch